Prosaposin acts as a neurotrophic factor, in addition to its role as the precursor protein for saposins A, B, C, and D, which are activators for specific sphingolipid hydrolases in lysosomes. In rats, the prosaposin gene generates two alternative splicing forms of mRNA: Pro+9 containing a 9-base insertion and Pro+0 without. The expression of these mRNAs changes after brain injury. We examined the expression patterns of the alternative splicing forms of prosaposin mRNA in the rat facial nerve nucleus for 52 days following facial nerve transection. Pro+0 mRNA increased within 3 days of transection, peaked after 5-10 days, and remained significantly elevated for 21 days. In contrast, the expression of Pro+9 mRNA was constant throughout the regenerative period. Prosaposin mRNA expression increased not only in facial motoneurons, but also in microglia during facial nerve regeneration. Our findings indicate that the saposin B domain of prosaposin, which is the domain affected by alternative splicing, plays an important role in both neurons and microglia during neuroregeneration.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neures.2007.09.010DOI Listing

Publication Analysis

Top Keywords

facial nerve
20
alternative splicing
16
splicing forms
12
prosaposin mrna
12
expression patterns
8
patterns alternative
8
forms prosaposin
8
mrna rat
8
rat facial
8
nerve nucleus
8

Similar Publications

Tic douloureux, also known as trigeminal neuralgia, is distinguished by recurrent episodes of severe, lancinating pain that affects one or more branches of the trigeminal nerve, representing a prevalent pain syndrome. This condition has an annual incidence rate of 27 per 100,000 individuals. Nevertheless, direct compression caused by vertebrobasilar dolichoectasia (VBD) represents a considerably less frequent etiology of trigeminal neuralgia, with an estimated overall incidence of about 1%.

View Article and Find Full Text PDF

The objective of the study was to assess the utility and safety of Temporo-masseteric Nerve Block (TMNB), and to explore the mechanism for its apparent sustained pain relief. This manuscript describes, (1) a retrospective study evaluating pain reduction in patients who received the TMNB injection for the management of masticatory myogeneous pain (myalgia, per Diagnostic Criteria for Temporomandibular Disorders (DC/TMD criteria)), and (2) a motor nerve conduction study (NCS) of the temporalis and masseter, performed in the absence of signs or symptoms of TMD, before and after the TMNB injection. The results were as follows.

View Article and Find Full Text PDF

To synthesize scientific knowledge regarding the prevalence of neuropathies and nerve injuries caused by dental implant placement in mandible and the available management. Observational and interventional studies evaluating neuropathies occurrence in adults who underwent dental implant surgery were included. Any neuropathy diagnostic was accepted.

View Article and Find Full Text PDF

Occipital nerve block for headaches: a narrative review.

J Oral Facial Pain Headache

June 2024

Departments of Anesthesiology and Pharmacology, Toxicology, and Neurosciences, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA 71103, USA.

The occipital nerve block involves the injection of a local anesthetic and possibly a corticosteroid near the occipital nerves at the base of the skull and aims at providing relief from chronic headaches by temporarily numbing or reducing inflammation around the occipital nerves. It has proven to be efficacious in treating chronic headaches, especially those that are refractory to medication; it is both diagnostic and therapeutic with symptom abatement from weeks to months. Occipital nerve blocks can be utilized alone or with standard-of-care therapy for various other headache conditions, such as cluster headaches, episodic headaches or chronic migraines.

View Article and Find Full Text PDF

The aim of this study was to compare the effectiveness of greater occipital nerve (GON) block and pulsed radiofrequency (PRF) treatment in chronic migraine patients. Seventy patients admitted to the Neurology and Algology outpatient clinic between September 2023 and December 2023 and diagnosed with chronic migraine according to The International Classification of Headache Disorders 3rd Edition (ICHD-3) criteria were included in the study. Patients were randomized into 2 groups to receive ultrasound-guided repeated GON block and PRF.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!